Kezar Life Sciences, Inc. (KZR)
Chart Events
Performance Outlook
| Previous Close | 5.67 |
| Open | 5.71 |
| Bid | 5.54 x 900 |
| Ask | 6.66 x 3100 |
| Day's Range | 5.60 - 5.74 |
| 52 Week Range | 4.24 - 7.40 |
| Volume | 65,186 |
| Avg. Volume | 281,998 |
| Market Cap | 271.173M |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Business Wire
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the formation of its Clinical Advisory Committee.
- Business Wire
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported results from the completed Phase 1b dose escalation portion of its MISSION study, evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in systemic lupus erythematosus (SLE) patients with and without nephritis. The data are being presented by Richard Furie, M.D., Chief of Division of Rhe
- Business Wire
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors.
